Neuroblastoma: An enigmatic disease

British Medical Bulletin

Volumn 52, Issue 4, 1996, Pages 787-801

  Brossard, Josée ^a   Bernstein, Mark L ^b   Lemieux, Bernard ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TENIPOSIDE; TUMOR MARKER;

ADRENAL GLAND; CANCER INCIDENCE; CANCER SCREENING; HUMAN; NEURAL CREST; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TRUNK;

EID: 0030444834     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011583     Document Type: Review

References (49)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2nd edn. Philadelphia: JB Lippincott, 1993; 739-68
2. Bernstein ML, Leclerc JM, Bunin G et al. A population based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992; 10: 323-9
3. Beckwith JB, Perrin EV. In situ neuroblastoma: a contribution to the natural history of neural crest tumors. Am J Pathol 1963; 43: 1089-104
4. Turkel SB, Itabashi HH. The natural history of neuroblastoma cells in the fetal adrenal gland. Am J Pathol 1974; 76: 225-44
5. Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 1992; 89: 114-8
6. Brodeur GM, Azar C, Brother M et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992; 70 suppl.: 1685-94
7. Caron H, van Sluis P, de Kraker J et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30
8. Schwab M, Alitalo K, Klempnauer KH et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983; 305: 245-8
9. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985; 313: 1111-6
10. Look AT, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 1990; 9: 581-91
11. Bourhis J, Dominici C, McDowell H et al. N-myc genomic content and DNA ploidy in stage IV-S neuroblastoma. J Clin Oncol 1991; 9: 1371-5
12. Brodeur GM, Hayes FA, Green AA et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987; 47: 4248-53
13. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311: 231-5
14. Brenner DW, Barranco SC, Winslow BH, Shaeffer J. Flow cytometric analysis of DNA content in children with neuroblastoma. J Pediatr Surg 1989; 24: 204-7
15. Taylor SR, Blatt J, Constantino JP, Roederer M, Murphy RF. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma: a 10-year retrospective study. Cancer 1988; 62: 749-54
16. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54
17. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-50
18. Vogan K, Bernstein ML, Leclerc JM et al. Absence of p53 mutations in primary neuroblastomas. Cancer Res 1993; 53: 5269-73
19. Tuchman M, Lemieux B, Auray-Blais C et al. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Pediatrics 1990; 86: 765-73
20. Chan HSL, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608-14
21. Norris MD, Bordow SB, Marshall GM et al. Expression of the gene for multidrug resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8
22. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-81
23. Brodeur GM, Prichard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77
24. Kushner BH, Cheung NKV, La Quaglia MP et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996; 14: 373-81
25. Pinkerton CR. Intensive chemotherapy with stem cell support-experience in paediatric solid tumours. Bull Cancer 1995; 82 suppl. 1: 61-5
26. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J Clin Oncol 1995; 13: 2789-95
27. 2S0000T antibody ch 14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A: 261-7
28. Bauer M, Reaman GH, Hank JA et al. A phase 2 trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Children's Cancer Group Study. Cancer 1995; 75: 2959-65
29. Sawada T, Todo S, Fujita K, Lino S, Imashuku S, Kusunoki T. Mass screening of neuroblastoma in infancy. Am J Dis Child 1982; 136: 710-2
30. Sawada T, Nakata T, Takasugi N et al. Mass screening for neuroblastoma in infants in Japan: interim report of a mass screening study group. Lancet 1984; ii: 271-3
31. Nishi M, Miyake H, Takeda T et al. Effects of the mass screening of neuroblastoma in Sapporo city. Cancer 1987; 60: 433-6
32. Naito H, Sasaki M, Yamashiro K et al. Improvement in prognosis of neuroblastoma through mass population screening. J Pediatr Surg 1990; 25: 245-8
33. Goodman S. Neuroblastoma screening data: an epidemiologic analysis. Am J Dis Child 1991; 145: 1415-22
34. Craft AW, Parker L. Poor prognosis neuroblastoma: is screening the answer? Br J Cancer 1992; 66 suppl. XVIII: S96-S101
35. Bessho F, Hashizume K, Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 1991; 119: 237-41
36. Murphy SB, Cohn SL, Craft AW et al. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on neuroblastoma screening. Lancet 1991; 337: 344-6
37. Nakagawara A, Zaizen Y, Ikeda K et al. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 1991; 9: 2037-44
38. Hachitanda Y, Ishimoto K, Hata J, Shimada H. One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 1994; 74: 3223-6
39. Suita S, Zaizen Y, Yano H et al. How to deal with advanced cases of neuroblastoma detected by mass screening: a report from the pediatric oncology study group of the Kyushu area of Japan. J Pediatr Surg 1994; 29: 599-603
40. Ishimoto K, Kiyokawa N, Fujita H et al. Problems of mass screening for neuroblastoma: analysis of false-negative cases. J Pediatr Surg 1990; 25: 398-401
41. Hayashi Y, Ohi R, Yaoita S et al. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds. J Pediatr Surg 1995; 30: 467-70
42. Bernstein ML, Woods WG. Screening for neuroblastoma: reporting for the Quebec Neuroblastoma Screening Project. In: Miller A, ed. Advances in Cancer Screening, 1996; In press
43. Woods WG, Tuchman M. Neuroblastoma: the case for screening infants in North America. Pediatrics 1987; 79: 869-73
44. Tuchman M, Auray-Blais C, Ramnaraine MLR, Neglia J, Krivit W, Lemieux B. Determination of urinary homovanillic and vanillylmandelic acid from dried filter paper samples: assessment of potential methods for neuroblastoma screening. Clin Biochem 1987; 20: 173-7
45. Scriver CR, Gregory D, Bernstein ML et al. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. CMAJ 1987; 136: 952-6
46. Auray-Blais C, Giguère R, Lemieux B. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening. Med Pediatr Oncol 1989; 17: 364-7
47. Tuchman M, Crippin PJ, Krivit W. Capillary gas-chromatographic determination of urinary homovanillic acid and vanillylmandelic acid. Clin Chem 1983; 29: 828-31
48. Woods WG, Tuchman M, Robison LL et al. Screening for neuroblastoma markedly increases the incidence in infants without reducing the incidence of unfavorable advanced stage disease in older children. Submitted, 1996
49. Esteve J. Some remarks on power calculation for neuroblastoma screening. Presented at the Third International Symposium on Neuroblastoma Screening, Kyoto, Japan, 1993